These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 14699054)

  • 21. [Fibroblast growth factor receptor and achondroplasia].
    Tanaka H
    Clin Calcium; 2006 Nov; 16(11):1888-93. PubMed ID: 17079857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achondroplasia: Development, pathogenesis, and therapy.
    Ornitz DM; Legeai-Mallet L
    Dev Dyn; 2017 Apr; 246(4):291-309. PubMed ID: 27987249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cytokines in bone diseases. FGF receptor signaling and achondroplasia/hypochondroplasia].
    Tanaka H
    Clin Calcium; 2010 Oct; 20(10):1490-6. PubMed ID: 20890030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains.
    Wang Q; Green RP; Zhao G; Ornitz DM
    Development; 2001 Oct; 128(19):3867-76. PubMed ID: 11585811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia.
    Martin L; Kaci N; Estibals V; Goudin N; Garfa-Traore M; Benoist-Lasselin C; Dambroise E; Legeai-Mallet L
    Hum Mol Genet; 2018 Jan; 27(1):1-13. PubMed ID: 29040558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I.
    d'Avis PY; Robertson SC; Meyer AN; Bardwell WM; Webster MK; Donoghue DJ
    Cell Growth Differ; 1998 Jan; 9(1):71-8. PubMed ID: 9438390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of FGF receptors by mutations in the transmembrane domain.
    Li Y; Mangasarian K; Mansukhani A; Basilico C
    Oncogene; 1997 Mar; 14(12):1397-406. PubMed ID: 9136983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular basis for the treatment of achondroplasia.
    Yamanaka Y; Ueda K; Seino Y; Tanaka H
    Horm Res; 2003; 60 Suppl 3():60-4. PubMed ID: 14671399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.
    Bellus GA; McIntosh I; Smith EA; Aylsworth AS; Kaitila I; Horton WA; Greenhaw GA; Hecht JT; Francomano CA
    Nat Genet; 1995 Jul; 10(3):357-9. PubMed ID: 7670477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
    Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
    Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
    Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
    Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
    Pannier S; Mugniery E; Jonquoy A; Benoist-Lasselin C; Odent T; Jais JP; Munnich A; Legeai-Mallet L
    Bone; 2010 Nov; 47(5):905-15. PubMed ID: 20673820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells.
    Krejci P; Bryja V; Pachernik J; Hampl A; Pogue R; Mekikian P; Wilcox WR
    Exp Cell Res; 2004 Jul; 297(1):152-64. PubMed ID: 15194433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia.
    Rousseau F; Bonaventure J; Legeai-Mallet L; Pelet A; Rozet JM; Maroteaux P; Le Merrer M; Munnich A
    Nature; 1994 Sep; 371(6494):252-4. PubMed ID: 8078586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The biological action of parathyroid hormone-related peptide (PTHrP) and fibroblast growth factor receptor 3 (FGFR3) on bone and cartilage.
    Amizuka N; Ozawa H; Sasaki T
    Kaibogaku Zasshi; 2000 Oct; 75(5):415-25. PubMed ID: 11155687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth.
    Mugniery E; Dacquin R; Marty C; Benoist-Lasselin C; de Vernejoul MC; Jurdic P; Munnich A; Geoffroy V; Legeai-Mallet L
    Hum Mol Genet; 2012 Jun; 21(11):2503-13. PubMed ID: 22367969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II.
    Shung CY; Ota S; Zhou ZQ; Keene DR; Hurlin PJ
    Hum Mol Genet; 2012 Nov; 21(21):4628-44. PubMed ID: 22843502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Differentiation of achondroplasia and other similar genetic dwarfism by FGFR3 gene analysis].
    Zhang Y; Yu W; Shen M; Fang Q; Fan M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Aug; 17(4):252-5. PubMed ID: 10932008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGFR3 targeting strategies for achondroplasia.
    Laederich MB; Horton WA
    Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations in the fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia, hypochondroplasia, and thanatophoric dysplasia: Taiwanese data.
    Tsai FJ; Tsai CH; Chang JG; Wu JY
    Am J Med Genet; 1999 Sep; 86(3):300-1. PubMed ID: 10482885
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.